US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.47

-0.0544-0.14%

Volume:26.43K

Turnover:1.02M

Market Cap:350.85M

PE:- -

High:38.62

Open:38.50

Low:38.35

Close:38.52

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:1.22

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Press Release: Antengene Announces 2026 Interim Results: Achieves First

The $3 billion short squeeze: anatomy of crypto’s biggest liquidation event since 2021

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

Bitcoin price breaks past $68K as $1B short squeeze hits

Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update

Virgin Trains gets green light for channel tunnel route

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PDS Biotech Reports Second Quarter 2026 Financial Results

Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

The Pivotal Moment for the Global Risk-Free Rate: A Dovish CPI Surprise Could Trigger a Short Squeeze in Bonds and Boost Risk Assets

Press Release: Erasca Reports Second Quarter 2026 Business Updates and Financial Results

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/ORR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.47,"timestamp":1788368397330,"preClose":38.5244,"halted":0,"volume":26434,"delay":0,"changeRate":-0.0014120920767098544,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Trading","change":-0.0544,"latestTime":"09-02 13:00:27 EDT","open":38.5,"high":38.62,"low":38.345,"amount":1017648.809782,"amplitude":0.007138,"askPrice":38.5,"askSize":656,"bidPrice":38.47,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.5244,"sharesOutstanding":12900000,"nav":38.93,"aum":355041600,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.53,"preClose":38.5244,"latestTime":"19:59 EDT","volume":54,"amount":2079.9308,"timestamp":1788307179128,"change":0.0056,"changeRate":0.000145,"amplitude":0},"volumeRatio":1.220585,"impliedVol":0.1424,"impliedVolPercentile":0.497},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.220585,"shares":9120000,"dividePrice":0,"high":38.62,"amplitude":0.007138,"preClose":38.5244,"low":38.345,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.47,"committee":-0.134948,"eps":0,"divideRate":0,"volume":26434,"delay":0,"ttmEps":0,"open":38.5,"prevYearClose":34.16,"prevWeekClose":38.9187,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":38.9814,"twentyDayClose":39.29,"sixtyDayClose":35.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663600336","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600336","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600336?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788178980,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy.-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","LU0053666078.USD","MTD","IE00BYQQ9H92.USD","BK4211","BK4533","BK4567","LU1093756168.USD","BK4121","IE00BFXG0V08.USD","BK1161","LU1093756325.SGD","BK4548","LU1223083913.SGD","IE00B5TLWC47.USD","CDE","BK4195","LU0210528500.USD","BK4107","SIL","BK4017","LU1721428933.USD","BK4588","LU2211817866.USD","LU2413666699.HKD","XME","BK1574","BK4585","02616","LU2413666426.HKD","LU1223082519.USD","LU2487616109.SGD","LU0347712357.USD","PFS","SGDM","GDXJ","L","LU1223082196.USD","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662955085","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2662955085","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662955085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:15","pubTimestamp":1787840100,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherapy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","LU2413666426.HKD","02616","SIL","BK1161","IE00B5TLWC47.USD","IE00BFXG0V08.USD","LU2487616109.SGD","LU2211817866.USD","GDXJ","L","PFS","LU2413666699.HKD","BK4567","BK4585","MTD","BK4121","BK4533","LU0347712357.USD","BK4195","LU1223082519.USD","BK4588","IND","BK4548","LU1093756325.SGD","ORR","BK1574","BK4017","LU0210528500.USD","LU1223083913.SGD","LU1721428933.USD","LU1223082196.USD","BK4211","IE00BYQQ9H92.USD","LU0053666078.USD","LU1093756168.USD","SGDM","BK4107","XME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085166","title":"Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085166","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085166?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:05","pubTimestamp":1787839500,"startTime":"0","endTime":"0","summary":"established out-licensing agreements for innovative products, and strong. -- Profit for the period reached US$64.9 million, and adjusted net profit. for the period[1] was approximately US$71.6 million, marking seven","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","ORR","CNS","MSS","R","AAQC","BK4113","02142","BK4232","BK4135","BK1574","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662888737","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662888737","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662888737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624700,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350174/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-phase-ii-clinical-study-for-first-line-treatment-of-esophageal-squamous-cell-carcinoma-advances-to-expansion-stage.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCZ","COAL","CBTJ","BFAP","CBXY","CBOY","BETE","BITX","XBTY","EZBC","MNRS","MAXI","YBTC","BITY","BTRN","BTCL","BITI","BCCC","BITU","HCC","FBTC","XHB","SBIT","ODD","BAGY","PD","CBXO","BRRR","DFII","BPI","ARKB","CBTA","CBOJ","BTCC","BTF","HODL","BTCW","CBOA","GBTC","PFS","QBF","BFJL","BITB","CBTY","CBOO","BITO","OC","BTC","DEFI","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","LU2413666699.HKD","CR","PFS","BK4077","ORR","LU2413666426.HKD","BK1161","BK4211","BK4533","LU0347712357.USD","BK4121","LU1093756168.USD","LU1093756325.SGD","09969","SLE","IND","BK1574","BK4585","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","BK4161","BK4195","BK4548","BK4588","MTD","IE00B5TLWC47.USD","BK4199","LU2211817866.USD","LU1721428933.USD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661410992","title":"Press Release: Antengene Announces 2026 Interim Results: Achieves First","url":"https://stock-news.laohu8.com/highlight/detail?id=2661410992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661410992?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:00","pubTimestamp":1787533200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYZ","COAL","CRS","HCC","BK4604","06996","IE00B66KJ199.SGD","BK1191","BK4161","LU0963586101.USD","BK4585","CR","IE00B7SZL793.SGD","XAR","BK4022","03160","BK4006","BK4099","BK4187","BK4232","BK4588","ORR","BK1574","LU2065731478.USD","BK1583","BK4555","IE0031619046.USD","R","TM","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661525287","title":"The $3 billion short squeeze: anatomy of crypto’s biggest liquidation event since 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2661525287","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661525287?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:25","pubTimestamp":1787289926,"startTime":"0","endTime":"0","summary":"Six weeks of bearish positioning ended in 24 hours. Here is how the trade unwound, who got caught, and whether the squeeze has legs.More than $3 billion in leveraged short positions were liquidated across crypto derivatives markets on Aug 19 and 20, 2026, making it the eighth largest liquidation event on record and the largest concentrated short squeeze since November 2021.Bitcoin climbed from an intraday low near $64,100 to a peak above $72,000, while Ethereum surged roughly 18% in 24 hours, its strongest single day move since March 2024.The U.S. Treasury doubled the maximum size of its liquidity support buyback operations for long dated bonds from $2 billion to $4 billion per operation, compressing yields and pushing risk assets higher.Binance absorbed approximately $518 million in liquidations, Hyperliquid roughly $513 million, and Bybit around $303 million, with short positions accounting for 92% of all forced closures.Then, over the span of 24 hours, it went violently higher.Bitco","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/3-billion-short-squeeze-anatomy-crypto-biggest-liquidation-2021-2/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/3-billion-short-squeeze-anatomy-crypto-biggest-liquidation-2021-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["ETHA","BKCH","SHRT","09042","CRPT","ETHW","BERZ","FFLS","OSSL","BITQ","HELS","TEKX","YETH","ETHV","QETH","ETU","HFEQ","WX","FETH","ETHD","LSEQ","ETH","ORR","RIVC","CLSE","LFGY","MEMY","STCE","NCIQ","IBIT","DAPP","TON.USD.CC","EZET","LITU","ETHU","BITW","FTLS","ETHE","LBAY","EETH","ETHT","GMEC","DWSH","BTC.USD.CC","GDLC","BTC.USD.HKCC","DIME","EVNT","HDGE","BTF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660770364","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660770364","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660770364?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:53","pubTimestamp":1787194380,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348072/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-abstract-published-by-wclc-extended-follow-up-shows-continued-efficacy-improvement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBXA","DFII","CBTA","QBF","BTCO","BITY","BFJL","BITB","BITO","BTCI","CBOA","BITX","BTF","HCC","CBTJ","FBTC","XBTY","BPI","IBIT","BETH","COAL","SBIT","BTC","BTCC","BFAP","OC","CBOO","CBTO","PD","PFS","BTCL","BETE","BTCZ","CBXY","ARKB","BTRN","HODL","BRRR","CBXJ","BTCW","ODD","GBTC","XHB","DEFI","MAXI","ORR","YBTC","BAGY","EZBC","BITI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660473611","title":"Bitcoin price breaks past $68K as $1B short squeeze hits","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473611","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473611?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:29","pubTimestamp":1787171394,"startTime":"0","endTime":"0","summary":"Bitcoin price surged past $68,000 late Wednesday as a break above crowded liquidation levels forced short sellers to buy back positions, turning a gradual recovery into a one-minute price spike of roughly 4%.Bitcoin price jumped from below $65,000 to a high near $69,500 before settling around $68,500.More than $1 billion in crypto shorts were reportedly liquidated within one hour.The breakout cleared a 4-hour double-bottom neckline near $65,400.Bitcoin now faces daily resistance between $69,000 and $70,000 after its RSI entered overbought territory.Market analyst Daan Crypto Trades said in an Aug. 19 X post that Bitcoin experienced a “massive squeeze” after crossing the $67,000 liquidation cluster. He said the resulting one-minute candle gained about 4%, exceeding the size of any full daily candle recorded in recent weeks.Bitcoin reversed the setup within minutes. Once BTC price crossed $67,000, exchanges began closing positions that no longer had enough collateral, requiring short sel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/bitcoin-price-breaks-past-68k-as-1b-short-squeeze-hits/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/bitcoin-price-breaks-past-68k-as-1b-short-squeeze-hits/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BITO","LSEQ","BFOC","WX","OOQB","IREC","QBF","RIVC","GMEC","BITX","BITK","DWSH","09008","EVNT","HELS","BERZ","LBAY","SHRT","IBIT","HDGE","CBXL","BTC.AU","CRPT","03439","FTLS","83042","BTC.USD.HKCC","CBTL","09439","BTC","CLSE","HFEQ","LITU","ISBG","ORR","CBXJ","CBOL","MEMY","RIOX","BESO","OSSL","03008","BTYB","09042","SPBC","STCE","BTC.USD.CC","NCIQ","FFLS","03042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461968","title":"Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461968?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:00","pubTimestamp":1787050800,"startTime":"0","endTime":"0","summary":"-- Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene. autoleucel, IMA203) remains on track to complete the required. randomizations by year-end to support final analysis for the primary PFS. -- Company plans to proceed directly to a streamlined final analysis for the. primary endpoint, PFS, while strengthening power for the secondary. endpoint, OS, to enhance the commercial product profile. -- SUPRAME topline data disclosure for the final PFS analysis expected in H1. -- Anzu-cel PRAME Cell Therapy: Updated Phase 1b data at ASCO 2026 continued. to show durable anti-tumor activity in metastatic melanoma, with 56% cORR,of 46%, as well as predictable and manageable tolerability. -- IMA203CD8 PRAME Cell Therapy: Updated Phase 1 data presented at ASCO 2026. demonstrated clinical activity in hard-to-treat gynecologic cancers with. a 63% ORR and 50% cORR; updated data across multiple PRAME-positive solid. -- IMA402 PRAME Bispecific: Phase 1b data at recommended Phase 2 dose . r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4211","BK4139","IMTX","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660714484","title":"Virgin Trains gets green light for channel tunnel route","url":"https://stock-news.laohu8.com/highlight/detail?id=2660714484","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660714484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:45","pubTimestamp":1786963506,"startTime":"0","endTime":"0","summary":"Virgin will break up Eurostar's decades-old monopoly over channel crossings Virgin Trains has moved a step closer to running train services between London and Paris, Amsterdam and Brussels, after the railway watchdog waved through its application to use the line connected London to the channel tunnel.The Office of Rail and Road  said on Monday it had given Sir Richard Branson’s train company the green light to run as many as 20 return services to continental Europe from October 2030 onwards, in a decision likely to herald the break-up of Eurostar’s decades-old monopoly of the route. The ruling marks a significant milestone for Virgin Trains’ hopes to run a rival channel tunnel service, which were first announced last year. Virgin hailed it as an “opportunity to bring competition” to a route that has solely been operated by Eurostar since it was launched in 1994.","market":"fut","thumbnail":"https://www.cityam.com/wp-content/uploads/2026/08/Virgin-to-move-ahead-with-cross-Channel-plans.png?w=286&h=161&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2026/08/Virgin-to-move-ahead-with-cross-Channel-plans.png?w=286&h=161&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/virgin-trains-gets-green-light-for-channel-tunnel-route/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/virgin-trains-gets-green-light-for-channel-tunnel-route/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659912921","title":"Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659912921","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659912921?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR (R)$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","ORR","PR","PXI","R","BK4161","FXN","CTXR","BK4022","BK4213","CTOR","BK4007","BK4139","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129230","title":"Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129230","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129230?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR(R) launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions ordering","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","TM","FXN","BK4139","BK4555","BK4099","R","DT","LU1169589451.USD","LU1169590202.USD","BK4232","LU0348723411.USD","BK4161","BK4588","BK4022","CTXR","BK4585","PR","BK4007","BK4560","BK4023","CR","BK4604","CTOR","03160","PXI","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659415671","title":"Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659415671","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659415671?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"TUDRIQEV in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345284/0/en/replimune-reports-fiscal-first-quarter-2027-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","NVIB","IDNA","HYLG","TBXU","BK4588","BK4585","BK4230","FBT","BK4539","GNOM","MEDX","SYNB","CR","CRBU","CAR","ORR","LD","CNCR","BK4161","BK4022","BK4195","PFS","GDOC","BK4139","IBB","BK4211","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","NVIB","ORR","BK4588","BK4585","MEDX","PFS","GDOC","PDS","BK4092","BK4211","BK4581","IDNA","HYLG","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658749839","title":"Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658749839","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658749839?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"patients that have been treated with a muzastotug dose of either 10 mg/kg. -- In the combined 10 mg/kg cohorts, muzastotug achieved an overall","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","COAL","BK4211","BK4195","ADAG","BK4232","R","BK4006","BK4139","HCC","BK4022","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101400396","title":"The Pivotal Moment for the Global Risk-Free Rate: A Dovish CPI Surprise Could Trigger a Short Squeeze in Bonds and Boost Risk Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1101400396","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101400396?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:53","pubTimestamp":1786528430,"startTime":"0","endTime":"0","summary":"Wall Street strategists are nearly as divided as possible on whether the Federal Reserve will resume rate hikes next month. One point, however, is undisputed: the U.S. CPI inflation report, set for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MUNX","UTWY","AGZD","VGLT","IBTK","TBJL","TLT","IGOV","BOXX","VGSH","MUB","AGIH","ZTmain","MWNmain","BBIB","USIN","BOND","ISHG","ZROZ","TLTX","GOLY","MYCN","BK4585","SGOV","TFJL","BBSB","LQD","DBND","SHV","BWZ","HYKE","USVN","HMOP","IBII","ZNmain","SBND","BSV","BITC","IBID","IBIE","TBT","TLTW","VGIT","UBmain","TSYW","GOVT","PRMN","NGHT","TYO","GBIL","UTRE","AGG","MINT","TBIL","CLSE","EDV","IEF","USHY","WAMA","TNmain","LIAJ","HYG","BNDW","TIP","ZFmain","BK4588","STIP","UTHY","VCIT","BWX","TMF","UBT","IBTH","UFIV","BK4550","FLGV","CIVG","IBIH","BK4504","SHRT","TLTI","RYSE","PFIX","ZBmain","XBIL","BND","MTNmain","JPST","ORR","TLH","BK4535","SCHO","LIBD","SHY","WTLS","BIL","IBIK","VCSH","BK4581","IEI","BBLB","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994859","title":"Press Release: Erasca Reports Second Quarter 2026 Business Updates and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994859?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:01","pubTimestamp":1786478460,"startTime":"0","endTime":"0","summary":"updated preliminary data from the ongoing AURORAS-1 Phase 1 trial in the. U.S., building on the Company's April 2026 announcement with additional. patients and longer follow-up. At the recommended dose for expansion.  of 32 mg once daily , ERAS-0015 demonstrated encouraging. monotherapy activity in second-line or later (2L+) KRAS G12X pancreatic. ductal adenocarcinoma , with a 57% uORR8wk and ongoing treatment. across all responding patients and most enrolled patients.1,2 ERAS-0015. , no treatment-related discontinuations, and a median relative dose. intensity of 100% at both the 24 mg QD and 32 mg QD RDEs.1 The Company","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","IE00B66KJ199.SGD","ERAS","ORR","LU1559883803.SGD","LU0566484027.USD","BK4187","IE0031619046.USD","ROKT","DCO","BK4139","IE00B7SZL793.SGD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658399001","title":"PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101","url":"https://stock-news.laohu8.com/highlight/detail?id=2658399001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658399001?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:25","pubTimestamp":1786451100,"startTime":"0","endTime":"0","summary":"PDS0301 Phase 2 clinical data in mCRC and a comprehensive review of capital allocation priorities drive strategic refocus designed to maximize long-term shareholder valuePRINCETON, N.J., Aug.  11, 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342690/37149/en/pds-biotech-announces-strategic-refocus-prioritizing-pds0301-in-metastatic-colorectal-cancer-mcrc-and-partnership-strategy-for-pds0101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS","BK4588","ORR","BK4581","PDS","BK4092","BK4585","BK4113","IDNA","XBI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":132,"code":"91000000","status":"200"}]}}